IME Medical Electrospinning Collaborates With StentIt to Develop Resorbable Endovascular Support Grafts

February 10, 2021—IME Medical Electrospinning announced that it has entered into a collaboration with StentIt for the development and production of regenerative endovascular support grafts.

According to the announcement, StentIt endovascular support grafts are designed to mimic the natural human extracellular matrix for implants in the human body in nanometer and micrometer format with a catheter-based approach. Human cells rebuild these matrices, leading to new body tissue. StentIt, based in Eindhoven, The Netherlands, is a medical device spin-off company from Eindhoven University of Technology.

Headquartered in Waalre, The Netherlands, IME’s manufacturing process applies specific polymers to create fiber-based medical devices that mimic the natural human extracellular matrix in nanometer and micrometer format for implants and membranes in the human body. Human cells recognize these artificial matrices (scaffolds) as the body’s own, facilitating the repair of the damaged tissue for heart valves, blood vessels, nerves, tendons, skin and bone, etc., stated the company.

“We are thrilled to join forces with IME Medical Electrospinning to further optimize our fibrillated endovascular implants,” commented StentIt Chief Executive Officer Bart Sanders, in the IME press release. “IME is a highly innovative and leading company in the field of medical electrospinning, for which I’m confident that together we will spur the development of a superior and reproducible product while getting StentIt ready to scale.”

Judith Heikoop, Chief Executive Officer of IME Medical Electrospinning, added, “We are extremely proud to have been able to expand our collaborations with such a promising company like StentIt. IME Medical Electrospinning develops medical devices in close collaboration with an ever-growing portfolio of customers and partners worldwide within the industry, the scientific environment, hospitals, and medical institutes. This collaboration is testimony to our strategic goal to become a trusted partner worldwide in codeveloping electrospun medical devices that will cause a revolution in the industry and will enable tissue rebuilding.”